Nirvana Life Sciences: New License For Psychedelics' Speedy Delivery Method

Canada's Nirvana Life Sciences Inc.  recently acquired a license for a novel delivery system for its psychedelics-based therapies currently in development. The company, which seeks to develop psychedelic therapeutic medicines including non-addictive chronic pain and relapse-prevention products, added this novel delivery system to its portfolio. The delivery system is destined for active pharmaceutical ingredients (APIs) with high bioavailability and rapid onset.   The system, manufactured for the licensor Hai Beverages Inc., will be used as a formulating agent for both water-soluble and non-water-soluble APIs . Their onset, when taken orally, ... Full story available on